Alnylam Pharmaceuticals Inc (NAS:ALNY)
$ 265.9 -3.05 (-1.13%) Market Cap: 34.30 Bil Enterprise Value: 33.17 Bil PE Ratio: 0 PB Ratio: 1,063.60 GF Score: 78/100

Alnylam Pharmaceuticals Inc to Discuss Regeneron Collaboration - Call Transcript

Apr 08, 2019 / 12:30PM GMT
Release Date Price: $90.17 (-2.82%)
Christine Regan Lindenboom
Alnylam Pharmaceuticals, Inc. - VP of IR & Communications

Good morning, I'm Christine Lindenboom, Vice President of Investor Relations and Corporate Communications at Alnylam. Thank you for joining us to discuss our new alliance with Regeneron to develop and commercialize RNAi therapeutics for central nervous system and ocular diseases.

With me today are John Maraganore, our Chief Executive Officer; Akshay Vaishnaw, President of R&D; Yvonne Greenstreet, Chief Operating Officer.

In addition, Barry Greene, our President; and Manmeet Soni, Chief Financial Officer, are with us and available for Q&A.

For those of you participating via conference call, the slides we've made available via webcast can also be accessed by going to the Investor page of our website, www.alnylam.com.

During today's call, as outlined on Slide 2, John will provide an overview of the new alliance we just announced with Regeneron for the development and commercialization of RNAi therapeutics for

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot